November 27, 2019Open Access

Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder

Key Points

Key points are not available for this paper at this time.

Abstract

Among patients with NMOSD, satralizumab added to immunosuppressant treatment led to a lower risk of relapse than placebo but did not differ from placebo in its effect on pain or fatigue. (Funded by Chugai Pharmaceutical; ClinicalTrials.gov number, NCT02028884.).

Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder

Key Points

Abstract

Cite This Study